1 Introduction Finerenone, a non-steroidal mineralocorticoid receptor antagonist, is indicated to slow kidney disease progression for patients with chronic kidney disease (CKD) and type 2 diabetes (T2DM) [1, 2] and to reduce cardiovascular outcomes among patients with heart failure (HF) and left ventricular ejection fraction (LVEF) ≥ 40% [3].
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Development Leverkusen
Contact Development Leverkusen, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack